Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lung cancer
Biotech
Zymeworks halts phase 2 ADC plans over 'clinical landscape'
Zymeworks has halted phase 2 plans for a HER2 antibody-drug conjugate while the biotech assesses the “evolving clinical landscape.”
James Waldron
Mar 7, 2024 9:00am
FDA lifts hold on Iovance's lung cancer cell therapy trial
Mar 4, 2024 9:44am
AstraZeneca places next ADC bet on in-house pipeline
Feb 21, 2024 8:00am
Roche leads Freenome's $254M fundraising for cancer blood tests
Feb 15, 2024 10:27am
Samsung taps Lunit to bring AI detection to its X-ray scanners
Jan 29, 2024 10:23am
Merus shares dip as lung cancer data reveal 3 patient deaths
Dec 4, 2023 1:04pm